Klaus Edvardsen

Klaus joined Nykode Therapeutics in 2022. He has extensive experience from leading drug development programs within oncology, hematology and infectious diseases in both biotech and pharma companies. His previous roles include Chief Development Officer of CureVac, and Senior Vice President and Head of Global Oncology Development of Merck KGaA, where he led early- and late-stage global oncology development. Prior to these roles, he served as Senior Vice President and Head of Global Medicines Development Oncology at AstraZeneca and various leadership roles at both GlaxoSmithKline and Genmab. Klaus Edvardsen holds a M.D. degree as well as a Ph.D. in cancer biology from University of Copenhagen.